Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: A systematic review

Hepatology

Volumn 52, Issue 6, 2010, Pages 2216-2222

  Hunt, Christine M ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMOXICILLIN PLUS CLAVULANIC ACID; ATORVASTATIN; AZATHIOPRINE; CERIVASTATIN; DIDANOSINE; ETHAMBUTOL; FLUINDOSTATIN; HALOTHANE; HLA DQB1 ANTIGEN; ISONIAZID; LAMIVUDINE; MEVINOLIN; PYRAZINAMIDE; RIFAMPICIN; SIMVASTATIN; STAVUDINE; TACRINE; ZIDOVUDINE;

DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; DRUG RECHALLENGE; FATTY ACID OXIDATION; HEPATITIS; HUMAN; HYPERSENSITIVITY; JAUNDICE; LIPID PEROXIDATION; LIVER CELL DAMAGE; LIVER INJURY; LIVER TOXICITY; METABOLITE; MITOCHONDRIAL MEMBRANE POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTITUBERCULAR AGENTS; AZATHIOPRINE; DRUG-INDUCED LIVER INJURY; HALOTHANE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MITOCHONDRIA, LIVER; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; TACRINE;

EID: 78649615066     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24022     Document Type: Review

References (57)

1. Andrade RJ, Robles M, Lucena MI. Rechallenge in drug-induced liver injury: the attractive hazard. Expert Opin Drug Saf 2009; 8: 709-714.
2. Papay JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, et al. Drug-induced liver injury following drug rechallenge. Regul Tox Pharm 2009; 54: 84-90.
3. Mushin WW, Rosen M, Jones EV. Posthalothane jaundice in relation to previous administration of halothane. Br Med J 1971; 3: 18-22.
4. Andrade RJ, Lucena MI, Fernandez MC, Pelaez G, Pachkoria K, Garcia-Ruiz E, etal. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
5. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 1994; 271: 991-998.
6. Sharma SK, Singla R, Sarda P, Mohan A, Makharia G, Jayaswal A, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-839.
7. Tahaoglu K, Atac G, Sevim T, Torun T, Yazicioglu O, Horzum G, et al. The management of anti-tuberculosis drug induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-69.
8. Boelsterli UA, Lim PLK. Mitochondrial abnormalities-A link to idiosyncratic drug hepatotoxicity? Toxicology and Applied Pharmacology 2007; 220: 92-107.
9. Lucena MI, García-Cortés M, Cuetoa R, Lopez-Durana JL, Andrade RJ. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008; 22: 141-158.
10. El-Serag HB, Everhart JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-1828.
11. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28.
12. Chinnery PF, Johnson MA, Wardell TM, Singh-Kler R, Hayes C, Brown DT, et al. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000; 48: 188-193.
13. Mehta R, Chan K, Lee O, Tafazoli S, O'Brien PG. Drug-associated mitochondrial toxicity. In: Dykens JA, Will Y, eds. Drug-Induced Mitochondrial Dysfunction. Hoboken, NJ: Wiley; 2008: 72-113.
14. Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Development Today 2007; 12: 777-785.
15. De Baar MP, De Ronde A. Mitochondrial toxicity of antiviral drugs: a challenge to accurate diagnosis. In: Dykens JA, Will Y, eds. Drug-Induced Mitochondrial Dysfunction. Hoboken, NJ: Wiley; 2008: 473-483.
16. Day CP, Stewart JD, Horvath R, Fontana RJ, Watkins PB, Bolst S, et al. Common POLG genetic variants increase the risk of sodium valproate-induced liver injury and failure [Abstract]. HEPATOLOGY 2009; 50: 382A.
17. McFarland R, Hudson G, Taylor RW, Green SH, Hodges S, McKiernan PJ, et al. Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase c (POLG1). Arch Dis Child 2008; 93: 151-153.
18. Andrade R, Martinez C, Ulzurrun E, Garcia-Martin E, Stephens C, Pelaez G. Relevance of manganese superoxide dismutase (SOD2 VAL16ALA) and glutathione peroxidase (GPX1 PRO198LEU) functional polymorphisms in patients with idiosyncratic drug-induced liver injury [Abstract]. HEPATOLOGY 2009; 50: 1161A.
19. Nelson MR. The International Serious Adverse Events Consortium (iSAEC) DILI genetics research update. AASLD 2010 Hepatotoxicity Meeting, Silver Spring, MD, March 24, 2010. Accessed April 27, 2010.
20. Spraggs C. HLA-DQA1*0201 is a major determinant of lapatinib-induced hepatotoxicity risk in women with advanced breast cancer. AASLD 2010 Hepatotoxicity Meeting, Silver Spring, MD, March 24, 2010. Accessed April 27, 2010.
21. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Peer I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
22. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008; 8: 186-195.
23. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RNM, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47: 717-720.
24. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem Res Toxicol 2008; 21: 84-92.
25. Agarwal VK, McHutchison JG, Hoofnagle JH; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8: 463-470.
26. National Institutes of Health. DailyMed drug list. Accessed March 17, 2010.
27. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330.
28. Podevin P, Biour M. Drug-induced allergic hepatitis. Clin Rev Allergy Immunol 1995; 13: 223-244.
29. Larrey D. Epidemiology and unique individual susceptibility to adverse drugs reactions affecting the liver. Semin Liver Dis 2002; 22: 135-145.
30. Hanley PJ, Ray J, Brandt U, Daut J. Halothane, isoflurane and sevoflurane inhibit NADH: ubiquinone oxidoreductase (complex I) of cardiac mitochondria. J Physiol 2002; 544: 687-693.
31. Ohlson KBE, Shabalina IG, Lennström K, Lindahl SGE, Nedergaard J. Inhibitory effects of halothane on the thermogenic pathway in brown adipocytes: localization to adenylyl cyclase and mitochondrial fatty acid oxidation. Biochem Pharmacol 2004; 68: 463-477.
32. Mansouri A, Haouzi D, Descatoire V, Demeilliers C, Sutton A, Vadrot N, et al. Tacrine inhibits topoisomerases and DNA synthesis to cause mitochondrial DNA depletion and apoptosis in mouse liver. HEPATOLOGY 2003; 38: 715-725.
33. De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 684-591.
34. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med 2005; 118: 618-624.
35. Kalgutkar AS, Didiukb MT. Structural alerts, reactive metabolites, and protein covalent binding: how reliable are these attributes as predictors of drug toxicity? Chem Biodivers 2009; 6: 2115-2136.
36. Kaufmann P, Török M, Zahno A, Waldhauser KM, Brecht K, Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria Cell Mol Life Sci 2006; 63: 2415-2425.
37. Dykens JA, Marroquin LD, Will Y. Strategies to reduce late stage drug attrition due to mitochondrial toxicity. Exp Rev Mol Diagnostics 2007; 7: 161-175.
38. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. HEPATOLOGY 1995; 21: 929-932.
39. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Resp Crit Care 2002; 166: 916-919.
40. Schwab CE, Tuschl H. In vitro studies on the toxicity of isoniazid in different cell lines Hum Exp Toxicol 2003; 22: 607-615.
41. Lucena MI, Andrade RJ, Fernandez MC, Pachkoria K, Pelaez G, Duran JA, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. HEPATOLOGY 2006; 44-856. 850-856.
42. Tapner NJ, Jones BE, Wu WM, Farrell GC. Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. J Hepatol 2004; 40: 454-463.
43. Shanmugarajan TS. Mitigation of azathioprine-induced oxidative hepatic injury by the flavonoid quercetin in wistar rats. Toxicol Mech Methods 2008; 18: 653-660.
44. Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, et al. Disposition of [1'-14C]stavudine after oral administration to humans. Drug Metab Dispos 2010; 38: 655-656.
45. Nunez M, Soriano V. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. Drug Saf 2005; 28: 53-66.
46. Dykens JA, Will Y. Drug-induced mitochondrial dysfunction. Hoboken, NJ: Wiley; 2008.
47. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 2008; 105: 97-105.
48. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. HEPATOLOGY 2005; 42: 481-489.
49. Dossing M, Andreasen PB. Drug-induced liver disease in Denmark: an analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs. Scand J Gastroenterol 1982; 17: 205-211.
50. Conforti A, Leone R, Ghiotto E, Velo G, Moretti U, Venegoni M, et al. Spontaneous reporting of drug-related hepatic reactions from two Italian regions (Lombardy and Veneto). Dig Liver Dis 2000; 32: 716-723.
51. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-1934.
52. Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. HEPATOLOGY 2010; 51: 615-620.
53. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4: 489-499.
54. Roth RA, Luyendyk JP, Maddox JF, Ganey PE. Inflammation and drug idiosyncrasy-is there a connection? J Pharmacol Exp Ther 2003; 307: 1-8.
55. Cosgrove BD, Kind BM, Hasan MA Alexopoulos LG, Farazi PA, Hendriks BS, et al. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009; 237: 317-330.
56. Suzuki A, Yuen N, Walsh JS, Papay J, Hunt CM, Diehl AM. Co-medications modulating liver injury and repair significantly influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol 2009; 7: 882-888.
57. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10: 1467-1487.